Lipid-based oral dosage forms - Regulatory perspective

American Pharmaceutical Review

Volumn 5, Issue 3, 2002, Pages 30-35

  Chen, Mei Ling ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CATECHOL METHYLTRANSFERASE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG VEHICLE; EPOXIDE HYDROLASE; ESTERASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HISTAMINE METHYLTRANSFERASE; LIPID; NEW DRUG; OXIDOREDUCTASE; SAQUINAVIR; SULFOTRANSFERASE; THIOPURINE METHYLTRANSFERASE; TOCOFERSOLAN; URIDINE TRIPHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STORAGE; DRUG TRANSPORT; LIPOPHILICITY; METHODOLOGY; MICROEMULSION; QUALITY CONTROL; SHELF LIFE;

EID: 0036742042     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. K. M. Wasan. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Develop. Indust. Pharm. 27:267-276 (2001).
2. W. N. Charman. Lipids, lipophilic drugs, and oral drug delivery -Some emerging concepts. J. Pharm. Sci. 89:967-978 (2000).
3. P. P. Constantinides. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm. Res. 12:1561-1572 (1995).
4. W. A. Ritschel. Microemulsions for improved peptide absorption from the gastrointestinal tract. Meth. Find. Exp. Clin. Pharmacol. 13:205-220 (1993).
5. S. Watnasirichaikul, N. M. Davies, T. Rades and I. G. Tucker. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsion. Pharm. Res. 17:684-689 (2000).
6. R. Roman. Challenges in the development of lipid-based formulations. AAPS Pharmaceutics and Drug Delivery Conference, Arlington, VA. April 22-24, 2002.
7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-- General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, October 2000.
8. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, August 2000.
9. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, September 1997.
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, August 1997.
11. C. von Corswant, P. Thoren and S. Engstrom. Triglyceride-based microemulsion for intravenous administration of sparingly soluble substances. J. Pharm. Sci. 87:200-208 (1998).
12. V. Pillay and R. Fassihi. A new method for dissolution studies of Lipid-filled capsules employing nifedipine as a model drug. Pharm. Res. 16:333-337 (1999).
13. U. S. Pharmacopeia 25/National Formulary 20, General Chapters, Physical Tests and Determinations, <711> Dissolution, p. 2011 (2002).
14. T. Chang, L. Z. Benet and M. F. Hebert. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:297-303 (1996).
15. J. M. Kovarik, E. A. Mueller, J. B. van Bree, W. Tetzloff and K. Kutz. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83:444-446 (1994).
16. J. E. Henney. Nationwide recall of SangCya oral solution. JAMA, 284(10):1234 (2000).